Background: Cardiovascular disease (CVD) mortality in schizophrenia is more frequent than
in the general population. Whether second-generation antipsychotics (SGAs) increase risk …

Background In many countries of the industrialised world second generation ('atypical')
antipsychotic drugs have become the first line drug treatment for people with schizophrenia …

Objective: To comprehensively review the 2 recent and large antipsychotic effectiveness
trials for treatment of schizophrenia: the United Kingdom's Cost Utility of the Latest …

Historically, schizophrenia has been associated with early-onset, persistent symptoms, and
progressive decline accompanied by poor functional recovery. The advent of effective drugs …

A large association study by O'Donovan et al recently suggested that genetic variation in
fibroblast growth factor receptor (FGFR) 2 increases the risk for developing schizophrenia …

Objective: To review clozapine's position in treatment algorithms for schizophrenia. Method:
Clozapine's status is reviewed in the context of its initial discovery and unique clinical and …

The large numbers of partial clozapine responders represent a major therapeutic challenge.
Unfortunately, there are no clear data to support how best to treat these patients. This study …

BACKGROUND: Clozapine-induced sialorrhea (CIS) is a subjective distressing adverse
effect and occurs in 31%–57% of schizophrenic patients receiving clozapine therapy …

Compared to both first-and second-generation antipsychotic drugs (APDs), clozapine shows
superior efficacy in treatment-resistant schizophrenia. In contrast to most APDs clozapine …

Objective: At therapeutic doses, classical antipsychotic drugs occupy a large proportion of
subcortical dopamine D2 receptors, whereas atypical antipsychotics preferentially occupy …